Oncology and Hematology - Global Oncology Academy

Episodes 81-96 of 390

Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
Management of HR+, HER2- High-Risk EBC
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
1.50 credits 10 episodes
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 credits 10 episodes
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
MinuteCE®
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
1.25 program credits
- Alan Venook, MD
1.25 program credits
Emerging Treatment Approaches for EBC
Emerging Treatment Approaches for EBC
MinuteCE®
Emerging Treatment Approaches for EBC
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
1.50 program credits
- William J. Gradishar, MD
1.50 program credits
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
MinuteCE®
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
1.25 program credits
- Alan Venook, MD
1.25 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
1.50 program credits
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Project Oncology®
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
- Charles Turck, PharmD, BCPS, BCCCP
- Thomas Egenod, MD
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Project Oncology®
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
- Ben Park, MD, PhD

Previous
1
2
…
4
5
6
7
8
…
24
25
Next

6/11